☰

Peter Black, MD - Publications

Affiliations: 
1987-2006 Neurosurgery Brigham and Women's Hospital, Boston 
Tree Info Similar researchers PubMed Report error

41 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Mostafid H, Babjuk M, Bochner B, Lerner SP, Witjes F, Palou J, Roupret M, Shariat S, Gontero P, van Rhijn B, Zigeuner R, Sylvester R, Comperat E, Burger M, Malavaud B, ... ... Black P, et al. Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. European Urology. PMID 32192815 DOI: 10.1016/J.Eururo.2020.03.005  0.307
2020 Au S, Keyes M, Black P, Villamil CF, Tavassoli P. Clinical and pathological characteristics of bladder cancer in post brachytherapy patients. Pathology, Research and Practice. 152822. PMID 31982182 DOI: 10.1016/J.Prp.2020.152822  0.359
2020 Necchi* A, Raggi D, Briganti A, Farè E, Giannatempo P, Marandino L, Gallina A, Bianchi M, Salonia A, Gandaglia G, Fossati N, Capitanio U, Montorsi F, Boormans J, Liu Y, ... ... Black P, et al. MP55-09 ASSOCIATION OF AN IMMUNE-GENE SIGNATURE WITH PATHOLOGIC RESPONSE AND OUTCOME AFTER NEOADJUVANT PEMBROLIZUMAB (PEMBRO), COMPARED TO NEOADJUVANT CHEMOTHERAPY (NAC), IN MUSCLE-INVASIVE BLADDER CANCER (MIBC) The Journal of Urology. 203: e841. DOI: 10.1097/Ju.0000000000000924.09  0.304
2019 Rouprêt M, Malmstrom PU, Black P. Recurrent Ta Low-grade Non-muscle-invasive Bladder Cancer: What Are the Options? European Urology Oncology. PMID 31239237 DOI: 10.1016/J.Euo.2019.06.003  0.345
2019 Lotan* Y, Boorjian S, Zhang J, Bivalacqua T, Lerner S, Porten S, Wheeler T, Hutchinson R, Francis F, Plessis Md, Davicioni E, Svatek R, Black P, Gibb E. MP26-15 MOLECULAR SUBTYPING REVEALS LUMINAL BLADDER TUMORS HAVE LOWER RATES OF PATHOLOGICAL UPSTAGING AT RADICAL CYSTECTOMY Journal of Urology. 201. DOI: 10.1016/S1569-9056(19)30467-1  0.313
2019 Costa JBD, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall’Era MA, Douglas J, Boormans L, Heijden MSVD, Wu C, Rhijn BWGV, ... ... Black P, et al. Molecular characterization of neuroendocrine-like bladder cancer European Urology Supplements. 18. DOI: 10.1016/S1569-9056(19)30464-6  0.311
2018 Lotan Y, Woldu SL, Sanli O, Black P, Milowsky MI. Modeling Cost-Effectiveness of a Biomarker-Based Approach to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. Bju International. PMID 29603871 DOI: 10.1111/Bju.14220  0.311
2018 Woldu S, Sanli O, Black P, Milowsky M, Lotan Y. Mp47-09 Cost-Effectiveness Analysis Of A Biomarker-Based Approach To Select Patients With Muscle-Invasive Bladder Cancer For Neoadjuvant Chemotherapy The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1488  0.309
2018 Duplisea J, Metcalfe M, Sundi D, Ferguson J, Li R, Pretzsch S, Kamat A, Navai N, Shah J, Bondaruk J, Czerniak B, Choi W, McConkey D, Black P, Dinney C. MP47-04 REFINING SELECTION CRITERIA FOR NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER: COMBINING CLINICAL RISK FEATURES AND INTRINSIC MOLECULAR SUBTYPES Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1483  0.311
2017 Frees SK, Aning J, Black P, Struss W, Bell R, Chavez-Munoz C, Gleave M, So AI. A prospective randomized pilot study evaluating an ERAS protocol versus a standard protocol for patients treated with radical cystectomy and urinary diversion for bladder cancer. World Journal of Urology. PMID 29116394 DOI: 10.1007/S00345-017-2109-2  0.312
2017 Khare SR, Aprikian A, Black P, Blais N, Booth C, Brimo F, Chin J, Chung P, Drachenberg D, Eapen L, Fairey A, Fleshner N, Fradet Y, Gotto G, Izawa J, et al. Quality indicators in the management of bladder cancer: A modified Delphi study. Urologic Oncology. PMID 28065393 DOI: 10.1016/J.Urolonc.2016.12.003  0.303
2017 Kawai Y, Zhang F, Akamatsu S, Hayashi T, Imada K, Beraldi E, Seiler R, Leong J, Oo H, Moskalev I, Fazli L, Sato A, Matsuyama H, Black P, Collins C, et al. Mp65-03 Inhibition Of Peg10 May Be A Novel Treatment Strategy For A Subset Of Bladder Cancer. The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1997  0.302
2017 Hayashi T, Sentani K, Kakumoto S, Oo HZ, Sakamoto N, Mutaguchi K, Kobatake K, Goto K, Inoue S, Teishima J, Black P, Matsubara A. MP04-07 PROGNOSTIC IMPACT OF IMMUNOHISTOCHEMICAL CLASSIFICATION OF BLADDER CANCER ACCORDING TO LUMINAL (UROPLAKIN III) AND BASAL (CYTOKERATIN 5/6) MARKERS Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.145  0.312
2017 Kiss B, Wyatt A, Douglas J, Skuginna V, Mo F, Anderson S, Rotzer D, Fleischmann A, Genitsch V, Hayashi T, Neuenschwander M, Buerki C, Davicioni E, Collins C, Thalmann G, ... Black P, et al. MP44-08 THE LANDSCAPE OF HER2 ALTERATIONS IN MUSCLE-INVASIVE BLADDER CANCER: IMPACT ON PATIENT SELECTION FOR TARGETED THERAPIES? Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1339  0.309
2017 Seiler R, Oo HZ, Todenhöfer T, Fazli L, Daugaard M, Black P. Mp34-05 The Prognostic Significance Of Tnm Staging In Bladder Cancer After Neoadjuvant Chemotherapy Can Be Enhanced With Tumor Regression Grading The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1022  0.323
2016 Singh P, Black P. Emerging role of checkpoint inhibition in localized bladder cancer. Urologic Oncology. PMID 27776977 DOI: 10.1016/J.Urolonc.2016.09.004  0.337
2016 Kassouf W, Aprikian A, Black P, Kulkarni G, Izawa J, Eapen L, Fairey A, So A, North S, Rendon R, Sridhar SS, Alam T, Brimo F, Blais N, Booth C, et al. Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 10: E46-80. PMID 26977213 DOI: 10.5489/Cuaj.3583  0.351
2016 Hooren Lv, Sandin L, Moskalev I, Ellmark P, Dimberg A, Black P, Tötterman TH, Mangsbo SM. Abstract B103: Intralesional administration of CTLA-4 blocking monoclonal antibodies as a means to optimize bladder cancer therapy Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B103  0.311
2016 Hayashi T, Goriki A, Oo HZ, Seiler R, Todenhofer T, Jaeger W, Awrey S, Altamirano-Dimas M, Fazli L, Matsubara A, Black P. Bladder Cancer: Basic Research & Pathophysiology IIIPD38-01 NOTCH2-HEY AXIS PROMOTES TUMOR GROWTH IN BLADDER CANCER THROUGH CELL CYCLE PROGRESSION AND DEDIFFERENTIATION The Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1481  0.327
2015 Baxter E, Dennis K, Kollmannsberger C, Black P, Attwell A, Morris WJ, Tyldesley S. Radical trimodality therapy for patients with locally advanced bladder cancer: The British Columbia Cancer Agency experience. Urologic Oncology. 33: 66.e13-9. PMID 25168459 DOI: 10.1016/J.Urolonc.2014.07.009  0.355
2015 Akamatsu S, Lynch K, Black P, Gleave M, Goldenberg L, Chi KN, So A. The impact of time to metastasis on survival in treatment-naïve prostate cancer patients. Journal of Clinical Oncology. 33: 212-212. DOI: 10.1200/Jco.2015.33.7_Suppl.212  0.342
2015 Hayashi T, Gust K, Jäger W, Awrey S, Li N, Altamirano-Dimas M, Buttyan R, Fazli L, Matsubara A, Black P. Mp36-17 Canonical Notch2 Signaling Promotes Tumor Growth And Metastasis In Bladder Cancer Through Cell Cycle Progression, Dedifferentiation And Emt The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.745  0.305
2015 Hayashi T, Seiler R, Bell RH, Ettinger S, Wang K, Awrey S, Gust K, Jäger W, Todenhoefer T, Altamirano-Dimas M, Matsubara A, Collins C, Black P. Mp49-09 Activation Of Ifn/Stat1 Signaling In Cisplatin/Gemcitabine Resistant Bladder Cancer The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.513  0.313
2014 Kapoor A, Dason S, Allard CB, Shayegan B, Lacombe L, Rendon R, Jacobsen NE, Fairey A, Izawa J, Black P, Tanguay S, Chin J, So A, Lattouf JB, Bell D, et al. The impact of method of distal ureter management during radical nephroureterectomy on tumour recurrence. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 8: E845-52. PMID 25485014 DOI: 10.5489/Cuaj.1985  0.307
2014 Black P. A new way of thinking about bladder cancer. Urology. 84: 1265-6. PMID 25312552 DOI: 10.1016/J.Urology.2014.08.013  0.307
2014 Fradet V, Mauermann J, Kassouf W, Rendon R, Jacobsen N, Fairey A, Izawa J, Kapoor A, Black P, Tanguay S, Chin J, So A, Lattouf JB, Bell D, Saad F, et al. Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration. Urologic Oncology. 32: 839-45. PMID 24856978 DOI: 10.1016/J.Urolonc.2014.04.006  0.337
2014 Zargar H, Aning J, Ischia J, So A, Black P. Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer. Nature Reviews. Urology. 11: 220-30. PMID 24619373 DOI: 10.1038/Nrurol.2014.52  0.312
2014 Black P, Kassouf W. Re: Günter Niegisch, Anja Lorch, Michael J. Droller, Hugh J. Lavery, Kristian D. Stensland, Peter Albers. Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit? Eur Urol 2013;64:355-7. European Urology. 65: e8-9. PMID 23972522 DOI: 10.1016/J.Eururo.2013.08.016  0.314
2014 Yafi FA, Tanguay S, Rendon R, Jacobsen N, Fairey A, Izawa J, Kapoor A, Black P, Lacombe L, Chin J, So A, Lattouf JB, Bell D, Fradet Y, Saad F, et al. Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. Urologic Oncology. 32: 31.e17-24. PMID 23428535 DOI: 10.1016/J.Urolonc.2012.11.014  0.312
2013 Williams AK, Kassouf W, Chin J, Rendon R, Jacobsen N, Fairey A, Kapoor A, Black P, Lacombe L, Tanguay S, So A, Lattouf JB, Bell D, Fradet Y, Saad F, et al. Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma. Urologic Oncology. 31: 1161-5. PMID 23415596 DOI: 10.1016/J.Urolonc.2011.12.004  0.328
2013 Fairey AS, Kassouf W, Estey E, Tanguay S, Rendon R, Bell D, Izawa J, Chin J, Kapoor A, Matsumoto E, Black P, So A, Lattouf JB, Saad F, Drachenberg D, et al. Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration. Bju International. 112: 791-7. PMID 23148712 DOI: 10.1111/J.1464-410X.2012.11474.X  0.307
2013 Black P. Using clinical practice guidelines in our own backyard: treating our patients with bladder cancer. Cuaj-Canadian Urological Association Journal. 4: 268-268. PMID 20694105 DOI: 10.5489/Cuaj.879  0.341
2013 Black P, So A. Perioperative chemotherapy for muscle-invasive bladder cancer Cuaj-Canadian Urological Association Journal. 3: 223-227. PMID 20019990 DOI: 10.5489/Cuaj.1202  0.328
2013 Black P. There is no role for focal therapy in prostate cancer. Cuaj-Canadian Urological Association Journal. 3: 331-332. PMID 19672449 DOI: 10.5489/Cuaj.1130  0.346
2013 Black P. Commentary on: Abiraterone in Metastatic Prostate Cancer Without Previous Chemotherapy Urology. 81: 1121-1122. DOI: 10.1016/J.Urology.2013.01.033  0.315
2013 Ischia J, Goldenberg L, So A, Black P, Gleave M. 1492 Biochemical Progression Free Survival After Radical Prostatectomy In Men With High-Risk Clinically Localised Prostate Cancer The Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2971  0.311
2012 Black P. Commentary on: Radical prostatectomy versus observation for localized prostate cancer. Urology. 80: 1181-1182. PMID 23040196 DOI: 10.1016/J.Urology.2012.07.055  0.307
2012 Inamoto T, Komura K, Black P, Katsuoka Y, Watsuji T, Azuma H. 1479 Clinically Significant Urethral Stricture And/Or Subclinical Urethral Stricture After High-Intensity Focused Ultrasound Paradoxically Correlates With Disease-Free Survival In Localized Prostate Cancer The Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.2000  0.313
2011 Black P. The Canadian Bladder Cancer Network: efforts to improve patient care Cuaj-Canadian Urological Association Journal. 5: 88-88. PMID 21470530 DOI: 10.5489/Cuaj.11050  0.375
2011 Kollmannsberger C, Tyldesley S, Moore C, Chi KN, Murray N, Daneshmand S, Black P, Duncan G, Hayes-Lattin B, Nichols C. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 22: 808-14. PMID 20926549 DOI: 10.1093/Annonc/Mdq466  0.332
2008 Kamat A, Black P, Dinney C, Grossman H, Siefker-Radtke A. POD-7.04: The Role for Radical Cystoprostatectomy in Patients with Clinical T4b Bladder Cancer Urology. 72. DOI: 10.1016/J.Urology.2008.08.157  0.314
Show low-probability matches.